FDA Approves Cilta-Cel for Treatment of Relapsed, Refractory

The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.

Related Keywords

Binod Dhakal , Janssen Research Development , Division Of Hematology , Janssen Biotech Inc , Oncologic Drugs Advisory Committee , Johnson , College Of Wisconsin , Janssen Biotech , Postmodern Studio , Drugs Advisory Committee , Study Comparing , Versus Pomalidomide , Participants With Relapsed , Lenalidomide Refractory Multiple Myeloma , Janssen Research , Medical College , Jordan Schecter , Innovative Medicine , Targeted Treatment Approved , Refractory Multiple Myeloma Who Have Received , Least One Prior Line , Standard Care , Lenalidomide Refractory Multiple ,